| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/20/2002 | US6436684 Isolated nucleic acid molecule consisting of selected nucleotide sequence encoding phenol sulfotransferase protein |
| 08/20/2002 | US6436683 Isolated polypeptide comprising selected amino acid sequence having nucleic acid methylase activity |
| 08/20/2002 | US6436642 Method of classifying a thyroid carcinoma using differential gene expression |
| 08/20/2002 | US6436637 Polynucleotide; expression vector; antiinflammatory agents; cell proliferative and apoptosis disorder treatment |
| 08/20/2002 | US6436629 Modulating angiogenesis |
| 08/20/2002 | US6436404 Antitumor |
| 08/20/2002 | US6436402 Process for making human papillomavirus virus-like particles with improved properties |
| 08/20/2002 | US6436390 IL8 inhibitors |
| 08/20/2002 | CA2335397C A method for screening compounds for their potential to inhibit neoplasia and pharmaceutical compositions containing such compounds |
| 08/20/2002 | CA2238283C Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| 08/20/2002 | CA2216129C Lactam-containing hydroxamic acids |
| 08/20/2002 | CA2203991C Methods and devices for immunizing a host to tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| 08/20/2002 | CA2145664C Oligonucleotides having a conserved g4 core sequence |
| 08/20/2002 | CA2110055C T cell receptor peptides as therapeutics for immune-related disease |
| 08/20/2002 | CA2098404C Improved humanized immunoglobulins |
| 08/20/2002 | CA2088367C Tri- and tetra-valent monospecific antigen-binding proteins |
| 08/20/2002 | CA2073983C Novel vitamin d analogues |
| 08/15/2002 | WO2002063010A2 Method of producing recombinant antibodies against tumors |
| 08/15/2002 | WO2002063008A2 Intracellular signaling molecules |
| 08/15/2002 | WO2002063007A2 TIMM8b-RELATED PROTEIN |
| 08/15/2002 | WO2002063006A2 Receptors and membrane-associated proteins |
| 08/15/2002 | WO2002063005A2 Lipid-associated molecules |
| 08/15/2002 | WO2002063004A2 G-protein coupled receptors |
| 08/15/2002 | WO2002062999A2 Proteins and nucleic acids encoding same |
| 08/15/2002 | WO2002062997A1 Novel protein and use thereof |
| 08/15/2002 | WO2002062979A2 Enzyme |
| 08/15/2002 | WO2002062972A2 Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| 08/15/2002 | WO2002062945A2 Compositions and methods relating to lung specific genes and proteins |
| 08/15/2002 | WO2002062852A1 Receptor protein expressed on cells |
| 08/15/2002 | WO2002062841A2 Secreted proteins |
| 08/15/2002 | WO2002062840A1 INTERFERON-α INDUCED GENE |
| 08/15/2002 | WO2002062838A1 Binding domain of siah (seven in absentia homolog) protein |
| 08/15/2002 | WO2002062813A1 Novel substance having physiological activity, process for producing the same, and use |
| 08/15/2002 | WO2002062810A2 Linkable sialyl lewis x analogs |
| 08/15/2002 | WO2002062804A1 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 08/15/2002 | WO2002062801A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension |
| 08/15/2002 | WO2002062800A1 Bicyclic nitrogenous fused-ring compound |
| 08/15/2002 | WO2002062799A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | WO2002062798A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | WO2002062794A2 Compounds |
| 08/15/2002 | WO2002062793A1 Thiazole compounds as tgf-beta inhibitors |
| 08/15/2002 | WO2002062792A1 Jnk inhibitor |
| 08/15/2002 | WO2002062789A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/15/2002 | WO2002062787A1 Pyrazoles as tgf inhibitors |
| 08/15/2002 | WO2002062777A2 Amino ceramide-like compounds and therapeutic methods of use |
| 08/15/2002 | WO2002062776A1 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors |
| 08/15/2002 | WO2002062773A1 Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors |
| 08/15/2002 | WO2002062763A2 Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas |
| 08/15/2002 | WO2002062756A1 Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as mmp inhibitors |
| 08/15/2002 | WO2002062755A2 Polyamide analogs as dna minor groove binders |
| 08/15/2002 | WO2002062753A1 Thiazolamines and their use as tgf-beta inhibitors |
| 08/15/2002 | WO2002062750A1 Cannabinoid receptor ligands |
| 08/15/2002 | WO2002062398A2 Radioactively labelled conjugates of phosphonates |
| 08/15/2002 | WO2002062369A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | WO2002062368A2 Method of inducing a ctl response |
| 08/15/2002 | WO2002062359A1 Preparation of cartilage extracts using organic solvents |
| 08/15/2002 | WO2002062350A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | WO2002062343A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| 08/15/2002 | WO2002062340A1 Highly lipophilic camptothecin prodrugs, methods of preparation, and formulations thereof |
| 08/15/2002 | WO2002062338A1 Parenteral formulation containing epothilone analogs |
| 08/15/2002 | WO2002062334A2 Cancer chemopreventative compounds and compositions and methods of treating cancers |
| 08/15/2002 | WO2002062293A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
| 08/15/2002 | WO2002050101A8 Retinoblastoma-binding protein |
| 08/15/2002 | WO2002042429A3 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| 08/15/2002 | WO2002042265A3 Cyanoguanidine prodrugs |
| 08/15/2002 | WO2002034753A3 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 08/15/2002 | WO2002032861A3 Orally active salts with tyrosine kinase activity |
| 08/15/2002 | WO2002030860A3 Ketone compounds and compositions for cholesterol management and related uses |
| 08/15/2002 | WO2002028866A3 Hydroxyesters of 7-desmethylrapamycin |
| 08/15/2002 | WO2002028821A3 Propionic acid derivatives with ppar-alpha activating properties |
| 08/15/2002 | WO2002026729A3 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/15/2002 | WO2002022212A8 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 08/15/2002 | WO2002022160A3 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 08/15/2002 | WO2002018554A3 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 08/15/2002 | WO2002013763A3 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 08/15/2002 | WO2002002050A3 Prevention and treatment of mycoplasma-associated diseases |
| 08/15/2002 | WO2002000263A3 Tripeptide prodrug compounds |
| 08/15/2002 | WO2001096307A3 Cycloalkyl alkanoic acids as integrin receptor antagonists |
| 08/15/2002 | WO2001095945A3 Prodrug compounds cleavable by thimet oligopeptidase |
| 08/15/2002 | WO2001091763A3 Extracts from spermatophyte plants with antitumor activity |
| 08/15/2002 | WO2001085995A9 Identification of neural defects associated with the nucleosom al assembly protein 1l2 gene |
| 08/15/2002 | WO2001081551A9 Retinal pigment epithelial cell lines with extended life-span and their applications |
| 08/15/2002 | WO2001079246A3 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
| 08/15/2002 | WO2001072685B1 Polyamine analogues as cytotoxic agents |
| 08/15/2002 | WO2001066753A3 Human genes and gene expression products |
| 08/15/2002 | WO2001044273A3 Receptor-selective somatostatin analogs |
| 08/15/2002 | WO2001040309A9 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| 08/15/2002 | WO2001032877A9 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 08/15/2002 | WO2001032843A9 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 08/15/2002 | WO2001032222A9 Selective toxin expression in angiogenic endothelial cells |
| 08/15/2002 | WO2001030768A9 Methods and compositions utilizing quinazolinones |
| 08/15/2002 | WO2001027135A9 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 08/15/2002 | WO2001019856A3 Secreted human proteins, polynucleotides encoding them and methods of using the same |
| 08/15/2002 | WO2000008048A3 Inhibitor of histone deacetylase |
| 08/15/2002 | US20020111505 Purified 15-epi-lipoxin compound has a longer tissue half-life; anticancer agents |
| 08/15/2002 | US20020111493 Amidino compounds useful as nitric oxide synthase inhibitors |
| 08/15/2002 | US20020111491 Antitumor agents, topoisomerase inhibitors, notoxic |
| 08/15/2002 | US20020111470 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof |
| 08/15/2002 | US20020111378 Inhibitors of IMPDH enzyme |
| 08/15/2002 | US20020111375 Antitumor agents |